A5015513362- Atrial Fibrillation Management and Outcomes
- Venous Thromboembolism Diagnosis and Management
- Intracerebral and Subarachnoid Hemorrhage Research
- Glutathione Transferases and Polymorphisms
- Advanced Glycation End Products research
- Acute Myocardial Infarction Research
- Blood transfusion and management
- Biochemical Acid Research Studies
- Mitochondrial Function and Pathology
- Antiplatelet Therapy and Cardiovascular Diseases
- Nitric Oxide and Endothelin Effects
- Pain Mechanisms and Treatments
- Cholinesterase and Neurodegenerative Diseases
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Sepsis Diagnosis and Treatment
- Diabetes and associated disorders
- Paraoxonase enzyme and polymorphisms
- Neurosurgical Procedures and Complications
- Chemical Reactions and Isotopes
- Blood donation and transfusion practices
- Skin Diseases and Diabetes
- Lipid metabolism and disorders
- Eicosanoids and Hypertension Pharmacology
- Biochemical effects in animals
- Clinical Laboratory Practices and Quality Control
Population Health Research Institute
2016-2023
Université Grenoble Alpes
2023
McMaster University
2016-2021
Karolinska Institutet
2006-2009
Academician Pilyugin Center
2003-2005
Genetika
2004-2005
Russian Research Center for Molecular Diagnostics and Therapy
2001-2003
Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal inhibitors.We evaluated 352 patients who had acute major bleeding within 18 hours after administration inhibitor. The received bolus andexanet, followed by 2-hour infusion. coprimary outcomes were the percent change in anti-factor activity andexanet treatment and percentage with excellent or good hemostatic efficacy at 12 end infusion, adjudicated on basis prespecified criteria. Efficacy was...
Andexanet alfa (andexanet) is a recombinant modified human factor Xa decoy protein that has been shown to reverse the inhibition of in healthy volunteers.
Andexanet alfa is a recombinant modified human FXa (factor Xa) developed to reverse inhibition from anticoagulants. Hemostatic efficacy and reversal of anti-FXa activity with andexanet were assessed in patients the ANNEXA-4 study (Andexanet Alfa, Novel Antidote Anticoagulation Effects Inhibitors) intracranial hemorrhage (ICrH).
Background and Purpose: It is unestablished whether andexanet alfa, compared with guideline-based usual care including prothrombin complex concentrates, associated reduced hematoma expansion (HE) mortality in patients factor-Xa inhibitor–related intracerebral hemorrhage (ICH). We the occurrence of HE clinical outcomes treated either alfa or during acute phase ICH. Methods: Data were extracted from multicenter, prospective, single-arm ANNEXA-4 trial (Andexanet Alfa, a Novel Antidote to...
Oxidative stress, resulting in a marked increase the level of oxygen free radicals (OFR), has been implicated etiology diabetic neuropathy (DN). Antioxidant enzymes may protect against rapid onset and progression DN, by reducing excess OFR peroxide. Mutations polymorphisms genes encoding such therefore result predisposition to DN. We investigated role two antioxidant enzymes, mitochondrial (Mn-SOD) extracellular (EC-SOD) superoxide dismutase, DN pathogenesis Russian population. studied...
Objective The aim of this study is to investigate the potential role functional myeloperoxidase (MPO) promoter polymorphisms in occurrence myocardial infarction (MI) Stockholm Heart Epidemiology Program. Methods and results Two MPO polymorphisms, −129G/A −463G/A, were genotyped Program population (n = 2774). −129A allele was associated with a lower risk MI women [odds ratio (OR) (95% confidence interval): 0.65 (0.43–0.98), P 0.03] but not men [OR: 1.12 (0.86–1.47), 0.38]. When stratified by...
Objective: This is an interim report of the Effects FXA Inhibitors (ANNEXA-4) study designed to evaluate use andexanet in patients with acute major bleeding. Background: Factor Xa (FXa) inhibitors are effective, but risk bleeding a concern and no specific antidotes available for reversal. Andexanet alfa has been developed as reversal agent FXa inhibitors. It shown reverse inhibition healthy volunteers. Design/Methods: The this multicenter, prospective, open-label, single-group included...
Актуальность Диабетическая нейропатия (ДН) относится к поздним сосудистым осложнениям сахарного диабета (СД). Основным метаболическим нарушением является гипергликемия. Повышенные концентрации глюкозы вызывают резкое повышение содержания свободных кислородных радикалов и продуктов перекисного окисления липидов (ПОЛ) в крови, что приводит организм состояние окислительного стресса. Каталаза одним из основных ферментов системы антиоксидантной защиты, осуществляющим разложение перекиси водорода...
Цель: исследование полиморфных маркеров генов-кандидатов для изучения генетической предрасположенности к развитию ДН. Материалы и методы: Для анализа мы обследовали 2 группы больных СД типа 1 - с наличием (ДН+, п=42) отсутствием ДН (ДН-, п=65). Анализ распределения аллелей генотипов в этих группах показал, что полиморфные маркеры Т174М М235Т гена AGT, А1166С AT2R1, A(-1903)G CMAI, С1167Тгена CAT, Ala(-9)VaI SOD2, Arg213Gly SOD3, Prol97Leu GPX1, Glnl92Arg PONI, Ala222Val MTHFR полиморфный...